NEW YORK, NY / September 22, 2022 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces that its project been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
A presentation named “Anticancer Gene Therapy Platform Addressing A Novel Target to Treat Patients” will showcase CLS’ data for the use of CLS-014 drug candidate as a platform technology to treat various cancers. CLS has identified a new therapeutic target for the successful anticancer therapy for multiple cancers: tumor- and neutrophils- derived cell-free DNA. Today, CLS revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies. The Company uses smart chimeric AAV technology for the delivery of the DNase I transgene to the liver, after which, hepatocytes start to produce a recombinant human DNase enzyme that destroys this cell-free DNA within tumor tissue.
The data that will be presented by Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics.
CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Cancer Metabolism and Signaling organized by the New York Academy of Sciences May 9, 2019, in New York, New York.
CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “CELL-FREE TUMOR DNA AND NEUTROPHIL EXTRACELLULAR TRAPS AS NOVEL THERAPEUTIC TARGETS FOR PANCREATIC CANCER” at the Frontiers in Cancer Immunotherapy organized by the New York Academy of Sciences May 14-15, 2019, in New York, New York.
NEW YORK, NY / April 06, 2021 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces presentation at the upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.